• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Emerg Crit Care Med . Clinical features of 162 fatal cases of COVID-19: a multi-center retrospective study

tetano

Editor, Senior Moderator
Emerg Crit Care Med


. 2022 Sep;2(3):109-115.
doi: 10.1097/EC9.0000000000000026. Epub 2022 Aug 30. Clinical features of 162 fatal cases of COVID-19: a multi-center retrospective study

Xianlong Zhou[SUP] 1 [/SUP], Guoyong Ding[SUP] 2 [/SUP], Qing Fang[SUP] 3 [/SUP], Jun Guo[SUP] 4 [/SUP], Luyu Yang[SUP] 5 [/SUP], Ping Wang[SUP] 2 [/SUP], Shou-Zhi Fu[SUP] 5 [/SUP], Ang Li[SUP] 1 [/SUP], Jian Xia[SUP] 1 [/SUP], Jiangtao Yu[SUP] 1 [/SUP], Jianyou Xia[SUP] 6 [/SUP], Min Ma[SUP] 4 [/SUP], Zhuanzhuan Hu[SUP] 4 [/SUP], Lei Huang[SUP] 4 [/SUP], Ruining Liu[SUP] 1 [/SUP], Cheng Jiang[SUP] 1 [/SUP], Shaoping Li[SUP] 1 [/SUP], Mingxia Yu[SUP] 7 [/SUP], Xizhu Xu[SUP] 2 [/SUP], Yan Zhao[SUP] 1 8 [/SUP], Quan Hu[SUP] 9 [/SUP], Weijia Xing[SUP] 2 [/SUP], Zhigang Zhao[SUP] 1 8 [/SUP]



Affiliations
Abstract

Background: The coronavirus disease 2019 (COVID-19) has affected approximately 2 million individuals worldwide; however, data regarding fatal cases have been limited.
Objective: To report the clinical features of 162 fatal cases of COVID-19 from 5 hospitals in Wuhan between December 30, 2019 and March 12, 2020.
Methods: The demographic data, signs and symptoms, clinical course, comorbidities, laboratory findings, computed tomographic (CT) scans, treatments, and complications of the patients with fatal cases were retrieved from electronic medical records.
Results: The median patient age was 69.5 (interquartile range: 63.0-77.25) years, and 80% of the patients were over 61 years. A total of 112 (69.1%) patients were men. Hypertension (45.1%) was the most common comorbidity, while 59 (36.4%) patients had no comorbidity. At admission, 131 (81.9%) patients had severe or critical COVID-19, whereas 39 (18.1%) patients with hypertension or chronic lung disease had moderate COVID-19. In total, 126 (77.8%) patients received antiviral treatment, while 132(81.5%) patients received glucocorticoid treatment. A total of 116 (71.6%) patients were admitted to the intensive care unit (ICU), and 137 (85.1%) patients received mechanical ventilation. Most patients received mechanical ventilation before ICU admission. Approximately 93.2% of the patients developed respiratory failure or acute respiratory distress syndrome. There were no significant differences in the inhospital survival time among the hospitals (P=0.14).
Conclusion: Young patients with moderate COVID-19 without comorbidity at admission could also develop fatal outcomes. The in-hospital survival time of the fatal cases was similar among the hospitals of different levels in Wuhan.

Keywords: Clinical features; Coronavirus disease 2019; Fatal cases; Survival time.

 
Back
Top Bottom